Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


CHMP positive recommendation for Eliquis (apixaban) to treat venous thromboembolism (VTE) and prevention of recurrent VTE in children – BMS + Pfizer

Written by | 19 Jun 2024 | Haematology

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Eliquis (apixaban).

The marketing authorisation holder for this medicinal product is Bristol-Myers Squibb/Pfizer EEIG. The CHMP adopted an extension to the existing indication to include treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in children, associated with the addition of new pharmaceutical forms and new strengths (0.15 mg granules in capsules for opening, as well as 0.5, 1.5 and 2 mg coated granules in sachet).

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.